CyFlow™ IgD Purified
| Antibody: | Yes |
| Antigen: | IgD |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | IA6-2 |
| Field of Interest: | Immunoglobulins, Immunophenotyping |
| Format/Fluorochrome: | Purified |
| Isotype: | IgG2a |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | AZ280259 |
For Research Use Only
| Concentration Unit | mg/mL |
| Concentration | 1 |
| Quantity | 0.1 mg |
| Volume | 0.1 mL |
| Immunogen | Human IgD |
| Background Information | Immunoglobulin D (IgD) is expressed on the surface of naive mature B cells, thus later than IgM, and is coexpressed with it then. Triggered by antigen binding, it signals through the CD79 complex to activate the B cells. Expression of IgD is lost after the isotype switch. Soluble IgD is present in very small amounts in the serum. IgD can bind to basophils and mast cells to activate them in an IgE-independent way to participate in respiratory immune defense. |
| Storage Buffer | The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Baier G, Baier-Bitterlich G, Looney DJ, Altman A: Immunogenic targeting of recombinant peptide vaccines to human antigen‑presenting cells by chimeric anti‑HLA‑DR and anti‑surface immunoglobulin D antibody Fab fragments in vitro. J Virol. 1995 Apr; 69(4):2357‑65. < PMID: 7533857 > | Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I: Regulation of inherently autoreactive VH4‑34 B cells in the maintenance of human B cell tolerance. J Clin Invest. 2001 Oct; 108(7):1061‑70. < PMID: 11581307 > | Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M, Avanzini MA, Marconi M, Badolato R, Ugazio AG, Levy Y, Catalan N, Durandy A, Tbakhi A, Notarangelo LD, Plebani A: Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci USA. 2001 Oct 23; 98(22):12614‑9. < PMID: 11675497 > | Di Sabatino A1, Carsetti R, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Tinozzi FP, Tinozzi S, Corazza GR: Immunoglobulin M memory B cell decrease in inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2004 Sep-Oct; 8(5):199‑203. < PMID: 15638230 > | Chang NH, McKenzie T, Bonventi G, Landolt-Marticorena C, Fortin PR, Gladman D, Urowitz M, Wither JE: Expanded population of activated antigen‑engaged cells within the naive B cell compartment of patients with systemic lupus erythematosus. J Immunol. 2008 Jan 15; 180(2):1276‑84. < PMID: 18178868 > | Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH: Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013 Mar; 8(3):382‑91. < PMID: 23293123 > | Degauque N, Ngono AE, Akl A, Lepetit M, Crochette R, Giral M, Lepourry J, Pallier A, Castagnet S, Dugast E, Guillot-Gueguen C, Jacq-Foucher M, Saulquin X, Cesbron A, Laplaud D, Nicot A, Brouard S, Soulillou JP: Characterization of antigen‑specific B cells using nominal antigen‑coated flow‑beads. PLoS One. 2013 Dec 30; 8(12):e84273. < PMID: 24386360 >